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OBJECTIVES: Narcolepsy is a chronic sleep disorder character-
ized by excessive daytime drowsiness, sleep attacks, cataplexy,
hypnagogic hallucinations and sleep paralysis. The aim of the
study was to assess the economic burden of patients suffering
from narcolepsy. METHODS: In a cross-sectional study, we used
a standardized telephone interview and a mailed questionnaire
to calculate the economic and social burden of 75 narcoleptic
patients (mean age: 48.9 ± 15.2; f :m: 29 :46), who met the Inter-
national Sleep Disorder Classiﬁcation criteria. Health-related
quality of life was assessed by using the SF-36 and the EQ-5D.
From a societal perspective, we calculated all direct and indirect
costs using EUR2002. RESULTS: The total annual costs
amounted to 16,798 ± 18,976€ per patient. Direct costs added
up to 3284 ± 3600€ and included hospital costs (1193 ± 2202€),
in-patient rehabilitation (535 ± 1772€), ambulatory diagnostics
(18 ± 3€0), ambulatory care (88 ± 55€) and drug costs (nar-
colepsy medication: 1120 ± 1530€). Approximately 50% of nar-
coleptic drug costs were due to the newer wake-promoting drug
Modaﬁnil. Modaﬁnil is known to be a potent but also more
expensive treatment. Total annual indirect costs were 13,515 ±
18,411€ per patient and are mainly caused by early retirement.
Sleep attacks correlated signiﬁcantly with early retirement and
higher indirect costs in comparison to patients without them (p
= 0.012). CONCLUSIONS: The socioeconomic impact of nar-
colepsy on society is considerably high. As in most other neuro-
logical diseases, the indirect costs outnumber the direct medical
costs. Appropriate treatment is required to help patients to con-
tinue their working life and to minimize indirect costs.
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OBJECTIVE: Comorbidities in patients with seizure disorders
impose signiﬁcant burdens on patients and families. The purpose
of this study was to assess the effect of comorbidities on medical
care use and cost among patients with partial seizure disorder
who were also refractory to anti-epileptic drug (AED) monother-
apy. METHODS: Retrospective data from PharMetrics claims
database, which includes 57 managed care plans, were collected
for adult patients treated with AEDs between January 1, 2000
and March 30, 2000. Patient data were analyzed over a 6-month
baseline period prior to treatment failure (on carbamazepine,
phenytoin, or valproic acid monotherapy), and over a 12-month
follow-up period. The Charlson Comorbidity Index (CCI) was
calculated for each patient. Econometric analysis of total cost
and a logistic regression with hospitalization as the dependent
variable, examined the impact of the CCI, controlling for age,
gender, geographic location, observation period, and AED
therapy during follow-up. RESULTS: Data from 549 patients
were analyzed. Sixty-percent of patients were male; 25.3% of
patients were 18–30 years old, 35.2% 31–45, and 39.5% were
≥46. Headache (10.6%), migraine (4.7%), depression (6.9%)
and brain tumor (4.0%) were frequently recorded, with
headache (p < 0.05) and migraine (p < 0.01) more common
among females. Hypertension and hyperlipidemia occurred most
often in the oldest age category (p < 0.001), being reported
among 20.3% and 10.1% of patients >46 years old. During
follow-up, among patients with a CCI > 1, the odds of hospi-
talization were nearly 3.5 times greater than for patients without
recorded comorbidities (OR = 3.46, p < 0.05), while treatment
costs for all medical care were 1.3 times greater (p < 0.10). CON-
CLUSIONS: These analyses suggest that, for patients refractory
to initial standard AED monotherapy, the presence of comor-
bidities substantially increase medical care use and costs for
managed care plans.
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OBJECTIVES: To assess the healthcare utilization of common
neuromuscular disease. METHODS: In total, 79 patients (mean
age: 53.9 ± 18.0; w/m: 45 :34) with Amyotrophic Lateral Scle-
rosis (ALS, n = 26), Myasthenia Gravis (MSG, n = 35) or
Facioscapulohumeral Muscular Dystrophy (FSHD, n = 18) were
interviewed for changes of employment and number of health
institution visits before the ﬁnal diagnosis has been established.
Additional health care utilization of the last 12 months were
assessed. RESULTS: The ﬁnal diagnosis has been established fol-
lowing an average of 3.4 ± 2.4 (ALS), 3.4 ± 2.8 (FSHD) and 2.5
± 1.6 (MSG) outpatient contacts with medical institution. The
number of hospitalizations until ﬁnal diagnosis was not differ-
ent for the three diseases (1.3 ± 1.0 (ALS), 1.1 ± 2.7 (FSHD) and
0.6 ± 06 (MSG)). For the last 12 months the patients reported
mean ambulant visits of 12 ± 9 (ALS), 6 ± 5 (FSHD) and 15 ±
10 (MSG). Hospitalization was reported by 85% of the ALS-,
16% of the FSHD-, and 74% of the MSG-patients. The mean
number of hospitalization was 1.23 ± 0.76 (ALS), 0.33 ± 0.77
(FSHD) and 1.31 ± 0.99 (MSG). Early retirement caused by the
neuromuscular disease was reported by 6% of the MSG patients,
19% of the ALS and 33% of the FSHD patients. Still at work
were 49% of the MSG, 56% of the FSHD and 12% of the ALS
patients. These patients were absent from work due to the neu-
romuscular disease for a mean of 14 ± 24d (ALS), 13 ± 17d
(MSG) and 5 ± 6d (FSHD). CONCLUSIONS: The results of the
study underline the socioeconomic impact of neuromuscular dis-
eases in Germany. Especially the high number of outpatient visits
during a 12-month period represent a relevant health care uti-
lization. In particular the inﬂuence of the employment state of
the patients contributes signiﬁcantly to the socioeconomic
impact on society.
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